CA2362476A1 - Integration de cellules progenitrices neurales transplantees dans les tissus nerveux de destinataires dystrophiques matures et immatures - Google Patents

Integration de cellules progenitrices neurales transplantees dans les tissus nerveux de destinataires dystrophiques matures et immatures Download PDF

Info

Publication number
CA2362476A1
CA2362476A1 CA002362476A CA2362476A CA2362476A1 CA 2362476 A1 CA2362476 A1 CA 2362476A1 CA 002362476 A CA002362476 A CA 002362476A CA 2362476 A CA2362476 A CA 2362476A CA 2362476 A1 CA2362476 A1 CA 2362476A1
Authority
CA
Canada
Prior art keywords
progenitor cells
cells
neural
recipient
neural progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362476A
Other languages
English (en)
Inventor
Michael J. Young
Fred H. Gage
Jasodhara Ray
Simon J. Whiteley
Henry Klassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Salk Institute for Biological Studies
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2362476A1 publication Critical patent/CA2362476A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)

Abstract

La présente invention concerne des méthodes de réparation des tissus nerveux différenciés dystrophiques, tels qu'une rétine endommagée ou malade ou un nerf optique endommagé ou malade, chez l'homme et autres animaux. L'invention concerne, en particulier, l'introduction de cellules progénitrices neurales dérivées de l'adulte au niveau d'un site tissulaire neural dystrophique d'un animal destinataire, y compris un animal adulte (mature), qu'il soit xénogénique, allogénique ou syngénique. Ces cellules progénitrices neurales dérivées de l'adulte peuvent s'intégrer fonctionnellement et morphologiquement dans les tissus nerveux dystrophiques matures et immatures.
CA002362476A 1999-02-11 2000-02-11 Integration de cellules progenitrices neurales transplantees dans les tissus nerveux de destinataires dystrophiques matures et immatures Abandoned CA2362476A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11964299P 1999-02-11 1999-02-11
US60/119,642 1999-02-11
PCT/US2000/003534 WO2000047238A1 (fr) 1999-02-11 2000-02-11 Integration de cellules progenitrices neurales transplantees dans les tissus nerveux de destinataires dystrophiques matures et immatures

Publications (1)

Publication Number Publication Date
CA2362476A1 true CA2362476A1 (fr) 2000-08-17

Family

ID=22385498

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362476A Abandoned CA2362476A1 (fr) 1999-02-11 2000-02-11 Integration de cellules progenitrices neurales transplantees dans les tissus nerveux de destinataires dystrophiques matures et immatures

Country Status (5)

Country Link
EP (1) EP1154801A4 (fr)
JP (1) JP2002536423A (fr)
AU (1) AU2878400A (fr)
CA (1) CA2362476A1 (fr)
WO (1) WO2000047238A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036749A2 (fr) * 2000-11-06 2002-05-10 The Salk Institute For Biological Studies Cellules souches de cadavres
JP2006506970A (ja) 2002-07-12 2006-03-02 ユニバーシティ オブ ワシントン 神経細胞の延長されたインビトロ培養のための方法および系
AU2003302707B2 (en) * 2002-12-02 2008-10-02 Anges Mg, Inc. Method for culturing neural stem cells using hepatocyte growth factor
US9061017B2 (en) 2006-05-03 2015-06-23 The Schepens Eye Research Institute, Inc. Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
WO2007130060A2 (fr) 2006-05-03 2007-11-15 Schepens Eye Research Isolation et application thérapeutique de cellules souches rétiniennes adultes prélevées sur des tissus extra-rétiniens
JO3626B1 (ar) * 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها

Also Published As

Publication number Publication date
JP2002536423A (ja) 2002-10-29
EP1154801A4 (fr) 2002-08-21
EP1154801A1 (fr) 2001-11-21
WO2000047238A9 (fr) 2001-07-26
AU2878400A (en) 2000-08-29
WO2000047238A1 (fr) 2000-08-17

Similar Documents

Publication Publication Date Title
Young et al. Neuronal differentiation and morphological integration of hippocampal progenitor cells transplanted to the retina of immature and mature dystrophic rats
Klassen et al. Stem cells and retinal repair
JP5414626B2 (ja) 幹細胞の移動および増殖を促進するための修飾されたピリミジン化合物の使用
Johnson et al. Development and characterization of an adult retinal explant organotypic tissue culture system as an in vitro intraocular stem cell transplantation model
Klassen et al. Isolation of retinal progenitor cells from post‐mortem human tissue and comparison with autologous brain progenitors
US6767738B1 (en) Method of isolating adult mammalian CNS-derived progenitor stem cells using density gradient centrifugation
Canola et al. Retinal stem cells transplanted into models of late stages of retinitis pigmentosa preferentially adopt a glial or a retinal ganglion cell fate
EP1261357B1 (fr) Isolation et transplantation de cellules souches retiniennes
Sharp et al. A re-assessment of long distance growth and connectivity of neural stem cells after severe spinal cord injury
Toda et al. Neurons generated from adult rat hippocampal stem cells form functional glutamatergic and GABAergic synapses in vitro
Dziewczapolski et al. Survival and differentiation of adult rat-derived neural progenitor cells transplanted to the striatum of hemiparkinsonian rats
Lu et al. Transplantation of EGF-responsive neurospheres from GFP transgenic mice into the eyes of rd mice
Van Den Pol et al. Olfactory ensheathing cells: time lapse imaging of cellular interactions, axonal support, rapid morphologic shifts, and mitosis
US20070037222A1 (en) Lineage restricted glial precursors
EP1040185A2 (fr) Cellules precurseurs neurales, leur procede de production et leur utilisation pour la therapie d'anomalies neurales
US8691207B2 (en) Transplantation of cells expressing markers for photoreceptor cells and retinal ganglion cells induced from Müller stem cells
WO2005089420A2 (fr) Expansion de cellules souches neurales avec lif
US6214334B1 (en) Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
Shetty et al. Neurite outgrowth from progeny of epidermal growth factor–responsive hippocampal stem cells is significantly less robust than from fetal hippocampal cells following grafting onto organotypic hippocampal slice cultures: Effect of brain‐derived neurotrophic factor
DE69924728T2 (de) Nicht-embryonale ependymale neuronale stammzellen und methoden zu ihrer isolierung
Zhang et al. Functional and histological improvement of the injured spinal cord following transplantation of Schwann cells transfected with NRG1 gene
CA2362476A1 (fr) Integration de cellules progenitrices neurales transplantees dans les tissus nerveux de destinataires dystrophiques matures et immatures
Zhou et al. A rat model for studying neural stem cell transplantation
WO2000047718A1 (fr) Isolation de cellules souches et leurs procedes d'utilisation
Simeonova Generation of Defined Astrocytic Phenotypes from Human Pluripotent Stem Cells for Transplantation after Spinal Cord Injury

Legal Events

Date Code Title Description
FZDE Dead